Physician profile
Rachel E Smith
NPI 1336663970
$1,910.19
in general payments reported to CMS, 2019-2025
22 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $386 · 2023: $441 · 2024: $196 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.99 | 2021-2025 | |
| Novo Nordisk INC | $467.24 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $118.18 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $86.05 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $70.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.46 | 2021-2023 | Trulance, Xifaxan |
| Pfizer INC. | $69.10 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $38.40 | 2021 | |
| Amarin Pharma, INC. | $38.13 | 2021 | |
| Esperion Therapeutics, INC. | $36.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.87 | 2022 | |
| Nalu Medical, INC. | $33.83 | 2025 | Nalu Neurostimulation System |
| Amgen INC. | $32.66 | 2023-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.23 | 2025 | Jardiance |
| Corcept Therapeutics | $29.29 | 2025 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.29 | 2021 | |
| Glaxosmithkline, LLC. | $24.18 | 2025 | Trelegy Ellipta |
| Inogen, INC. | $23.50 | 2024 | |
| Astellas Pharma US INC | $22.80 | 2024 | Veozah |
| Azurity Pharmaceuticals, INC. | $19.94 | 2025 | Azmiro |
| Biohaven Pharmaceuticals, INC. | $12.34 | 2021 | |
| Genentech USA, INC. | $7.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.